Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 8Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Sarcoma 4Endometrial Neoplasms 4Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Glioblastoma 2Solid Tumors 1Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Central Nervous System Neoplasms 1Bone Neoplasms 1

Interventions

Ifosfamide 17Methotrexate 16Doxorubicin 14Filgrastim 13Etoposide 12Cisplatin 12Cyclophosphamide 10Gemcitabine 9Leucovorin 8Sirolimus 6Carboplatin 6Topotecan 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Temozolomide 4Sorafenib 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Docetaxel 4trimetrexate glucuronate 3temsirolimus 3dinutuximab 3cixutumumab 3apatinib 3Vincristine 3Specimen Handling 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Osteosarcoma × ridaforolimus × Clear all
NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
216 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡